866-997-4948(US-Canada Toll Free)

Generics Global Industry Guide-2017

Published By :

MarketLine

Published Date : Feb 2017

Category :

Pharmaceutical

No. of Pages : 248 Pages

Generics Global Industry Guide_2017

Summary

Global Generics industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the global generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends and leading companies.

- For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The market value is evaluated at ex-factory prices.
- Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume.
- All currency conversions were calculated at constant average annual 2015 exchange rates.
- The global generics market is expected to generate total revenues of $318bn in 2016, representing a compound annual growth rate (CAGR) of 11.1% between 2012 and 2016.
- Market consumption volume is forecast to increase with a CAGR of 1.4% between 2012 and 2016, to reach a total of 78.6% of total pharma volume in 2016.
- The onset of the global economic crisis has led to several countries strengthening their generic policies. These policies have contributed to the strong growth experienced in this market in recent years.

Scope

- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the global generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global generics market
- Leading company profiles reveal details of key generics market players global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the global generics market with five year forecasts by both value and volume

Reasons to buy

- What was the size of the global generics market by value in 2016?
- What will be the size of the global generics market in 2021?
- What factors are affecting the strength of competition in the global generics market?
- How has the market performed over the last five years?
- Who are the top competitors in the global generics market?
Table of Contents
EXECUTIVE SUMMARY
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
Global Generics
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Generics in Asia-Pacific
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Generics in Europe
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Generics in France
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Germany
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Italy
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Japan
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Australia
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Canada
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in China
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The Netherlands
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Spain
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The United Kingdom
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The United States
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
About MarketLine

List of Tables
Table 1: Global generics market value: $ billion, 201216
Table 2: Global generics market volume: % of total pharma volume, 201216
Table 3: Global generics market geography segmentation: $ billion, 2016
Table 4: Global generics market value forecast: $ billion, 201621
Table 5: Global generics market volume forecast: % of total pharma volume, 201621
Table 6: Asia-Pacific generics market value: $ billion, 201216
Table 7: AsiaPacific generics market volume: % of total pharma volume, 201216
Table 8: AsiaPacific generics market geography segmentation: $ billion, 2016
Table 9: Asia-Pacific generics market value forecast: $ billion, 201621
Table 10: AsiaPacific generics market volume forecast: % of total pharma volume, 201621
Table 11: Europe generics market value: $ billion, 201216
Table 12: Europe generics market volume: % of total pharma volume, 201216
Table 13: Europe generics market geography segmentation: $ billion, 2016
Table 14: Europe generics market value forecast: $ billion, 201621
Table 15: Europe generics market volume forecast: % of total pharma volume, 201621
Table 16: France generics market value: $ billion, 201216
Table 17: France generics market volume: % of total pharma volume, 201216
Table 18: France generics market geography segmentation: $ billion, 2016
Table 19: France generics market value forecast: $ billion, 201621
Table 20: France generics market volume forecast: % of total pharma volume, 201621
Table 21: France size of population (million), 201216
Table 22: France gdp (constant 2005 prices, $ billion), 201216
Table 23: France gdp (current prices, $ billion), 201216
Table 24: France inflation, 201216
Table 25: France consumer price index (absolute), 201216
Table 26: France exchange rate, 201216
Table 27: Germany generics market value: $ billion, 201216
Table 28: Germany generics market volume: % of total pharma volume, 201216
Table 29: Germany generics market geography segmentation: $ billion, 2016
Table 30: Germany generics market value forecast: $ billion, 201621
Table 31: Germany generics market volume forecast: % of total pharma volume, 201621
Table 32: Germany size of population (million), 201216
Table 33: Germany gdp (constant 2005 prices, $ billion), 201216
Table 34: Germany gdp (current prices, $ billion), 201216
Table 35: Germany inflation, 201216
Table 36: Germany consumer price index (absolute), 201216
Table 37: Germany exchange rate, 201216
Table 38: Italy generics market value: $ billion, 201216
Table 39: Italy generics market volume: % of total pharma volume, 201216
Table 40: Italy generics market geography segmentation: $ billion, 2016
Table 41: Italy generics market value forecast: $ billion, 201621
Table 42: Italy generics market volume forecast: % of total pharma volume, 201621
Table 43: Italy size of population (million), 201216
Table 44: Italy gdp (constant 2005 prices, $ billion), 201216
Table 45: Italy gdp (current prices, $ billion), 201216
Table 46: Italy inflation, 201216
Table 47: Italy consumer price index (absolute), 201216
Table 48: Italy exchange rate, 201216
Table 49: Japan generics market value: $ billion, 201216
Table 50: Japan generics market volume: % of total pharma volume, 201216
Table 51: Japan generics market geography segmentation: $ billion, 2016
Table 52: Japan generics market value forecast: $ billion, 201621
Table 53: Japan generics market volume forecast: % of total pharma volume, 201621
Table 54: Japan size of population (million), 201216
Table 55: Japan gdp (constant 2005 prices, $ billion), 201216
Table 56: Japan gdp (current prices, $ billion), 201216
Table 57: Japan inflation, 201216
Table 58: Japan consumer price index (absolute), 201216
Table 59: Japan exchange rate, 201216
Table 60: Australia generics market value: $ billion, 201216
Table 61: Australia generics market volume: % of total pharma volume, 201216
Table 62: Australia generics market geography segmentation: $ billion, 2016
Table 63: Australia generics market value forecast: $ billion, 201621
Table 64: Australia generics market volume forecast: % of total pharma volume, 201621
Table 65: Australia size of population (million), 201216
Table 66: Australia gdp (constant 2005 prices, $ billion), 201216
Table 67: Australia gdp (current prices, $ billion), 201216
Table 68: Australia inflation, 201216
Table 69: Australia consumer price index (absolute), 201216
Table 70: Australia exchange rate, 201216
Table 71: Canada generics market value: $ billion, 201216
Table 72: Canada generics market volume: % of total pharma volume, 201216
Table 73: Canada generics market geography segmentation: $ billion, 2016
Table 74: Canada generics market value forecast: $ billion, 201621
Table 75: Canada generics market volume forecast: % of total pharma volume, 201621
Table 76: Canada size of population (million), 201216
Table 77: Canada gdp (constant 2005 prices, $ billion), 201216
Table 78: Canada gdp (current prices, $ billion), 201216
Table 79: Canada inflation, 201216
Table 80: Canada consumer price index (absolute), 201216
Table 81: Canada exchange rate, 201216
Table 82: China generics market value: $ billion, 201216
Table 83: China generics market volume: % of total pharma volume, 201216
Table 84: China generics market geography segmentation: $ billion, 2016
Table 85: China generics market value forecast: $ billion, 201621
Table 86: China generics market volume forecast: % of total pharma volume, 201621
Table 87: China size of population (million), 201216
Table 88: China gdp (constant 2005 prices, $ billion), 201216
Table 89: China gdp (current prices, $ billion), 201216
Table 90: China inflation, 201216
Table 91: China consumer price index (absolute), 201216
Table 92: China exchange rate, 201216
Table 93: Netherlands generics market value: $ billion, 201216
Table 94: Netherlands generics market volume: % of total pharma volume, 201216
Table 95: Netherlands generics market geography segmentation: $ billion, 2016
Table 96: Netherlands generics market value forecast: $ billion, 201621
Table 97: Netherlands generics market volume forecast: % of total pharma volume, 201621
Table 98: Netherlands size of population (million), 201216
Table 99: Netherlands gdp (constant 2005 prices, $ billion), 201216
Table 100: Netherlands gdp (current prices, $ billion), 201216
Table 101: Netherlands inflation, 201216
Table 102: Netherlands consumer price index (absolute), 201216
Table 103: Netherlands exchange rate, 201216
Table 104: Spain generics market value: $ billion, 201216
Table 105: Spain generics market volume: % of total pharma volume, 201216
Table 106: Spain generics market geography segmentation: $ billion, 2016
Table 107: Spain generics market value forecast: $ billion, 201621
Table 108: Spain generics market volume forecast: % of total pharma volume, 201621
Table 109: Spain size of population (million), 201216
Table 110: Spain gdp (constant 2005 prices, $ billion), 201216
Table 111: Spain gdp (current prices, $ billion), 201216
Table 112: Spain inflation, 201216
Table 113: Spain consumer price index (absolute), 201216
Table 114: Spain exchange rate, 201216
Table 115: United Kingdom generics market value: $ billion, 201216
Table 116: United Kingdom generics market volume: % of total pharma volume, 201216
Table 117: United Kingdom generics market geography segmentation: $ billion, 2016
Table 118: United Kingdom generics market value forecast: $ billion, 201621
Table 119: United Kingdom generics market volume forecast: % of total pharma volume, 201621
Table 120: United Kingdom size of population (million), 201216
Table 121: United Kingdom gdp (constant 2005 prices, $ billion), 201216
Table 122: United Kingdom gdp (current prices, $ billion), 201216
Table 123: United Kingdom inflation, 201216
Table 124: United Kingdom consumer price index (absolute), 201216
Table 125: United Kingdom exchange rate, 201216
Table 126: United States generics market value: $ billion, 201216
Table 127: United States generics market volume: % of total pharma volume, 201216
Table 128: United States generics market geography segmentation: $ billion, 2016
Table 129: United States generics market value forecast: $ billion, 201621
Table 130: United States generics market volume forecast: % of total pharma volume, 201621
Table 131: United States size of population (million), 201216
Table 132: United States gdp (constant 2005 prices, $ billion), 201216
Table 133: United States gdp (current prices, $ billion), 201216
Table 134: United States inflation, 201216
Table 135: United States consumer price index (absolute), 201216
Table 136: United States exchange rate, 201215
Table 137: Allergan plc: key facts
Table 138: Allergan plc: key financials ($)
Table 139: Allergan plc: key financial ratios
Table 140: Mylan Inc.: key facts
Table 141: Mylan Inc.: key financials ($)
Table 142: Mylan Inc.: key financial ratios
Table 143: Sandoz International GmbH: key facts
Table 144: Teva Pharmaceutical Industries Limited: key facts
Table 145: Teva Pharmaceutical Industries Limited: key financials ($)
Table 146: Teva Pharmaceutical Industries Limited: key financial ratios
Table 147: Sun Pharmaceutical Industries Ltd.: key facts
Table 148: Sun Pharmaceutical Industries Ltd.: key financials ($)
Table 149: Sun Pharmaceutical Industries Ltd.: key financials (Rs.)
Table 150: Sun Pharmaceutical Industries Ltd.: key financial ratios
Table 151: Sanofi SA: key facts
Table 152: Sanofi SA: key financials ($)
Table 153: Sanofi SA: key financials ()
Table 154: Sanofi SA: key financial ratios
Table 155: Les Laboratoires Servier: key facts
Table 156: STADA Arzneimittel AG: key facts
Table 157: STADA Arzneimittel AG: key financials ($)
Table 158: STADA Arzneimittel AG: key financials ()
Table 159: STADA Arzneimittel AG: key financial ratios
Table 160: Daiichi Sankyo Co., Ltd.: key facts
Table 161: Daiichi Sankyo Co., Ltd.: key financials ($)
Table 162: Daiichi Sankyo Co., Ltd.: key financials ()
Table 163: Daiichi Sankyo Co., Ltd.: key financial ratios
Table 164: Sawai Pharmaceutical Co., Ltd.: key facts
Table 165: Sawai Pharmaceutical Co., Ltd.: key financials ($)
Table 166: Sawai Pharmaceutical Co., Ltd.: key financials ()
Table 167: Sawai Pharmaceutical Co., Ltd.: key financial ratios
Table 168: Aspen Pharmacare Holdings Ltd: key facts
Table 169: Aspen Pharmacare Holdings Ltd: key financials ($)
Table 170: Aspen Pharmacare Holdings Ltd: key financials (ZAR)
Table 171: Aspen Pharmacare Holdings Ltd: key financial ratios
Table 172: Apotex, Inc.: key facts
Table 173: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts
Table 174: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)
Table 175: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)
Table 176: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios
Table 177: Esteve Group: key facts

List of Figures
Figure 1: Global generics market value: $ billion, 201216
Figure 2: Global generics market volume: % of total pharma volume, 201216
Figure 3: Global generics market geography segmentation: % share, by value, 2016
Figure 4: Global generics market value forecast: $ billion, 201621
Figure 5: Global generics market volume forecast: % of total pharma volume, 201621
Figure 6: Forces driving competition in the global generics market, 2016
Figure 7: Drivers of buyer power in the global generics market, 2016
Figure 8: Drivers of supplier power in the global generics market, 2016
Figure 9: Factors influencing the likelihood of new entrants in the global generics market, 2016
Figure 10: Factors influencing the threat of substitutes in the global generics market, 2016
Figure 11: Drivers of degree of rivalry in the global generics market, 2016
Figure 12: Asia-Pacific generics market value: $ billion, 201216
Figure 13: AsiaPacific generics market volume: % of total pharma volume, 201216
Figure 14: AsiaPacific generics market geography segmentation: % share, by value, 2016
Figure 15: Asia-Pacific generics market value forecast: $ billion, 201621
Figure 16: AsiaPacific generics market volume forecast: % of total pharma volume, 201621
Figure 17: Forces driving competition in the generics market in Asia-Pacific, 2016
Figure 18: Drivers of buyer power in the generics market in Asia-Pacific, 2016
Figure 19: Drivers of supplier power in the generics market in Asia-Pacific, 2016
Figure 20: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific, 2016
Figure 21: Factors influencing the threat of substitutes in the generics market in Asia-Pacific, 2016
Figure 22: Drivers of degree of rivalry in the generics market in Asia-Pacific, 2016
Figure 23: Europe generics market value: $ billion, 201216
Figure 24: Europe generics market volume: % of total pharma volume, 201216
Figure 25: Europe generics market geography segmentation: % share, by value, 2016
Figure 26: Europe generics market value forecast: $ billion, 201621
Figure 27: Europe generics market volume forecast: % of total pharma volume, 201621
Figure 28: Forces driving competition in the generics market in Europe, 2016
Figure 29: Drivers of buyer power in the generics market in Europe, 2016
Figure 30: Drivers of supplier power in the generics market in Europe, 2016
Figure 31: Factors influencing the likelihood of new entrants in the generics market in Europe, 2016
Figure 32: Factors influencing the threat of substitutes in the generics market in Europe, 2016
Figure 33: Drivers of degree of rivalry in the generics market in Europe, 2016
Figure 34: France generics market value: $ billion, 201216
Figure 35: France generics market volume: % of total pharma volume, 201216
Figure 36: France generics market geography segmentation: % share, by value, 2016
Figure 37: France generics market value forecast: $ billion, 201621
Figure 38: France generics market volume forecast: % of total pharma volume, 201621
Figure 39: Forces driving competition in the generics market in France, 2016
Figure 40: Drivers of buyer power in the generics market in France, 2016
Figure 41: Drivers of supplier power in the generics market in France, 2016
Figure 42: Factors influencing the likelihood of new entrants in the generics market in France, 2016
Figure 43: Factors influencing the threat of substitutes in the generics market in France, 2016
Figure 44: Drivers of degree of rivalry in the generics market in France, 2016
Figure 45: Germany generics market value: $ billion, 201216
Figure 46: Germany generics market volume: % of total pharma volume, 201216
Figure 47: Germany generics market geography segmentation: % share, by value, 2016
Figure 48: Germany generics market value forecast: $ billion, 201621
Figure 49: Germany generics market volume forecast: % of total pharma volume, 201621
Figure 50: Forces driving competition in the generics market in Germany, 2016
Figure 51: Drivers of buyer power in the generics market in Germany, 2016
Figure 52: Drivers of supplier power in the generics market in Germany, 2016
Figure 53: Factors influencing the likelihood of new entrants in the generics market in Germany, 2016
Figure 54: Factors influencing the threat of substitutes in the generics market in Germany, 2016
Figure 55: Drivers of degree of rivalry in the generics market in Germany, 2016
Figure 56: Italy generics market value: $ billion, 201216
Figure 57: Italy generics market volume: % of total pharma volume, 201216
Figure 58: Italy generics market geography segmentation: % share, by value, 2016
Figure 59: Italy generics market value forecast: $ billion, 201621
Figure 60: Italy generics market volume forecast: % of total pharma volume, 201621
Figure 61: Forces driving competition in the generics market in Italy, 2016
Figure 62: Drivers of buyer power in the generics market in Italy, 2016
Figure 63: Drivers of supplier power in the generics market in Italy, 2016
Figure 64: Factors influencing the likelihood of new entrants in the generics market in Italy, 2016
Figure 65: Factors influencing the threat of substitutes in the generics market in Italy, 2016
Figure 66: Drivers of degree of rivalry in the generics market in Italy, 2016
Figure 67: Japan generics market value: $ billion, 201216
Figure 68: Japan generics market volume: % of total pharma volume, 201216
Figure 69: Japan generics market geography segmentation: % share, by value, 2016
Figure 70: Japan generics market value forecast: $ billion, 201621
Figure 71: Japan generics market volume forecast: % of total pharma volume, 201621
Figure 72: Forces driving competition in the generics market in Japan, 2016
Figure 73: Drivers of buyer power in the generics market in Japan, 2016
Figure 74: Drivers of supplier power in the generics market in Japan, 2016
Figure 75: Factors influencing the likelihood of new entrants in the generics market in Japan, 2016
Figure 76: Factors influencing the threat of substitutes in the generics market in Japan, 2016
Figure 77: Drivers of degree of rivalry in the generics market in Japan, 2016
Figure 78: Australia generics market value: $ billion, 201216
Figure 79: Australia generics market volume: % of total pharma volume, 201216
Figure 80: Australia generics market geography segmentation: % share, by value, 2016
Figure 81: Australia generics market value forecast: $ billion, 201621
Figure 82: Australia generics market volume forecast: % of total pharma volume, 201621
Figure 83: Forces driving competition in the generics market in Australia, 2016
Figure 84: Drivers of buyer power in the generics market in Australia, 2016
Figure 85: Drivers of supplier power in the generics market in Australia, 2016
Figure 86: Factors influencing the likelihood of new entrants in the generics market in Australia, 2016
Figure 87: Factors influencing the threat of substitutes in the generics market in Australia, 2016
Figure 88: Drivers of degree of rivalry in the generics market in Australia, 2016
Figure 89: Canada generics market value: $ billion, 201216
Figure 90: Canada generics market volume: % of total pharma volume, 201216
Figure 91: Canada generics market geography segmentation: % share, by value, 2016
Figure 92: Canada generics market value forecast: $ billion, 201621
Figure 93: Canada generics market volume forecast: % of total pharma volume, 201621
Figure 94: Forces driving competition in the generics market in Canada, 2016
Figure 95: Drivers of buyer power in the generics market in Canada, 2016
Figure 96: Drivers of supplier power in the generics market in Canada, 2016
Figure 97: Factors influencing the likelihood of new entrants in the generics market in Canada, 2016
Figure 98: Factors influencing the threat of substitutes in the generics market in Canada, 2016
Figure 99: Drivers of degree of rivalry in the generics market in Canada, 2016
Figure 100: China generics market value: $ billion, 201216
Figure 101: China generics market volume: % of total pharma volume, 201216
Figure 102: China generics market geography segmentation: % share, by value, 2016
Figure 103: China generics market value forecast: $ billion, 201621
Figure 104: China generics market volume forecast: % of total pharma volume, 201621
Figure 105: Forces driving competition in the generics market in China, 2016
Figure 106: Drivers of buyer power in the generics market in China, 2016
Figure 107: Drivers of supplier power in the generics market in China, 2016
Figure 108: Factors influencing the likelihood of new entrants in the generics market in China, 2016
Figure 109: Factors influencing the threat of substitutes in the generics market in China, 2016
Figure 110: Drivers of degree of rivalry in the generics market in China, 2016
Figure 111: Netherlands generics market value: $ billion, 201216
Figure 112: Netherlands generics market volume: % of total pharma volume, 201216
Figure 113: Netherlands generics market geography segmentation: % share, by value, 2016
Figure 114: Netherlands generics market value forecast: $ billion, 201621
Figure 115: Netherlands generics market volume forecast: % of total pharma volume, 201621
Figure 116: Forces driving competition in the generics market in the Netherlands, 2016
Figure 117: Drivers of buyer power in the generics market in the Netherlands, 2016
Figure 118: Drivers of supplier power in the generics market in the Netherlands, 2016
Figure 119: Factors influencing the likelihood of new entrants in the generics market in the Netherlands, 2016
Figure 120: Factors influencing the threat of substitutes in the generics market in the Netherlands, 2016
Figure 121: Drivers of degree of rivalry in the generics market in the Netherlands, 2016
Figure 122: Spain generics market value: $ billion, 201216
Figure 123: Spain generics market volume: % of total pharma volume, 201216
Figure 124: Spain generics market geography segmentation: % share, by value, 2016
Figure 125: Spain generics market value forecast: $ billion, 201621
Figure 126: Spain generics market volume forecast: % of total pharma volume, 201621
Figure 127: Forces driving competition in the generics market in Spain, 2016
Figure 128: Drivers of buyer power in the generics market in Spain, 2016
Figure 129: Drivers of supplier power in the generics market in Spain, 2016
Figure 130: Factors influencing the likelihood of new entrants in the generics market in Spain, 2016
Figure 131: Factors influencing the threat of substitutes in the generics market in Spain, 2016
Figure 132: Drivers of degree of rivalry in the generics market in Spain, 2016
Figure 133: United Kingdom generics market value: $ billion, 201216
Figure 134: United Kingdom generics market volume: % of total pharma volume, 201216
Figure 135: United Kingdom generics market geography segmentation: % share, by value, 2016
Figure 136: United Kingdom generics market value forecast: $ billion, 201621
Figure 137: United Kingdom generics market volume forecast: % of total pharma volume, 201621
Figure 138: Forces driving competition in the generics market in the United Kingdom, 2016
Figure 139: Drivers of buyer power in the generics market in the United Kingdom, 2016
Figure 140: Drivers of supplier power in the generics market in the United Kingdom, 2016
Figure 141: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom, 2016
Figure 142: Factors influencing the threat of substitutes in the generics market in the United Kingdom, 2016
Figure 143: Drivers of degree of rivalry in the generics market in the United Kingdom, 2016
Figure 144: United States generics market value: $ billion, 201216
Figure 145: United States generics market volume: % of total pharma volume, 201216
Figure 146: United States generics market geography segmentation: % share, by value, 2016
Figure 147: United States generics market value forecast: $ billion, 201621
Figure 148: United States generics market volume forecast: % of total pharma volume, 201621
Figure 149: Forces driving competition in the generics market in the United States, 2016
Figure 150: Drivers of buyer power in the generics market in the United States, 2016
Figure 151: Drivers of supplier power in the generics market in the United States, 2016
Figure 152: Factors influencing the likelihood of new entrants in the generics market in the United States, 2016
Figure 153: Factors influencing the threat of substitutes in the generics market in the United States, 2016
Figure 154: Drivers of degree of rivalry in the generics market in the United States, 2016
Figure 155: Allergan plc: revenues & profitability
Figure 156: Allergan plc: assets & liabilities
Figure 157: Mylan Inc.: revenues & profitability
Figure 158: Mylan Inc.: assets & liabilities
Figure 159: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 160: Teva Pharmaceutical Industries Limited: assets & liabilities
Figure 161: Sun Pharmaceutical Industries Ltd.: revenues & profitability
Figure 162: Sun Pharmaceutical Industries Ltd.: assets & liabilities
Figure 163: Sanofi SA: revenues & profitability
Figure 164: Sanofi SA: assets & liabilities
Figure 165: STADA Arzneimittel AG: revenues & profitability
Figure 166: STADA Arzneimittel AG: assets & liabilities
Figure 167: Daiichi Sankyo Co., Ltd.: revenues & profitability
Figure 168: Daiichi Sankyo Co., Ltd.: assets & liabilities
Figure 169: Sawai Pharmaceutical Co., Ltd.: revenues & profitability
Figure 170: Sawai Pharmaceutical Co., Ltd.: assets & liabilities
Figure 171: Aspen Pharmacare Holdings Ltd: revenues & profitability
Figure 172: Aspen Pharmacare Holdings Ltd: assets & liabilities
Figure 173: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability
Figure 174: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *